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Abstract
A highly conserved sequence upstream of the transcriptional enhancer in the U3 of murine leukemia viruses (MLVs) was reported to
mediate negative regulation of their expression. In transient expression studies, negative regulation was reported to be conferred by
coexpression of the transcription factor YY1, which binds to a motif in the upstream conserved region (UCR). To address the function of
the UCR and its YY1-motif in an in vivo model of MLV–host interactions we introduced six consecutive triple basepair mutations into this
region of the potent T-lymphomagenic SL3-3 MLV. We report that all mutants have retained their replication competence and that they all,
like the SL3-3 wild type (wt), induce T-cell lymphomas when injected into newborn mice of the SWR strain. However, all mutants induced
disease with slightly shorter latency periods than the wt SL3-3, suggesting that the YY1 motif as well as its immediate context in the UCR
have a negative effect on the pathogenicity of the virus. This result may have implications for the design of retroviral vectors.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Murine leukemia virus (MLV) isolates may induce a
variety of tumors in the hematopoietic compartment when
injected into newborn mice of inbred strains. For prototypic,
potent disease-inducing viruses, such as Moloney, Friend,
and SL3-3 MLVs, critical determinants of disease induction
have been assigned to a region of U3 termed the transcrip-
tional enhancer (Chatis et al., 1984; DesGroseillers and
Jolicoeur, 1984; Lenz et al., 1984). The enhancer comprises
direct tandem repeats with densely packed recognition mo-
tifs for several cellular transcription factors, and a number
of studies have further determined a critical function of
many of these motifs for the pathogenicity and specificity of
the virus (Ethelberg et al., 1997b; Hallberg et al., 1991).
However, not only the enhancer sequences but also se-
quences upstream of the enhancer (Baum et al., 1995; Baum
et al., 1997; Flanagan et al., 1989; Wahlers et al., 2002b) or
between the enhancer and the promoter (Hanecak, Patten-
gale, and Fan, 1991; Ishimoto et al., 1987; Laimins et al.,
1984; Li et al., 1987; Tupper et al., 1992) may serve to
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modulate the transcriptional activity of the virus in a general
or tissue-specific manner. Few reports have addressed the
role of such cis-acting sequences in models of MLV disease
induction (Ishimoto et al., 1987; Tupper et al., 1992; Yo-
shimura and Diem, 1995).
We here look into the role of the upstream conserved
region (UCR) (AGTAACGCCATTTTGCAAGG) (Fig. 1),
which is highly conserved among MLV isolates (Golemis,
Speck, and Hopkins, 1990). The UCR sequence was first
reported to negatively regulate expression from the en-
dogenous B34 MLV LTR (Flanagan et al., 1989). Subse-
quently, the UCR sequence was used as a DNA probe to
isolate the UCR binding protein (UCRBP), now commonly
referred to as YY1. YY1 was found to mediate negative
regulation of reporter gene transcription driven from a
Moloney MLV LTR in transient expression assays (Flana-
gan et al., 1992). The reported negative effect of the YY1
site on transcription driven by a Moloney MLV LTR has an
impact on the design of retroviral vectors. The widely used
MND vector, which is based on the myeloproliferative
sarcoma virus, harbors a deletion of a fragment encompass-
ing the UCR (Challita et al., 1995). This deletion made the
MND vector superior to its parental construct with respect
to expression in embryonal carcinoma cells (Osborne et al.,
1999). However, it was not investigated to what extent this
difference was caused by removal of the YY1 motif or by
other cis-elements. A recent study has investigated the role
of the UCR and flanking sequences for expression of retro-
viral vectors based on the myeloproliferative sarcoma virus
or the polycythemic strain of spleen focus-forming virus
(Wahlers et al., 2002a). It was found that deletion of a 59-bp
fragment (from 34 to 94 of the provirus sequence)
caused about a twofold reduction of expression rates in the
lymphoid and hematopoietic cell lines investigated. This
reduction could, at least in part be attributed to the binding
site for NFAT (nuclear factor of activated T cells) within the
deleted region downstream of the YY1 motif (Rao, Luo, and
Hogan, 1997). Sequence comparison (Fig. 1B) indicates
Fig. 1. Map of UCR structure and introduced mutations. (A) Schematic organization of the U3 region of SL3-3 LTR, including the UCR and the enhancer
repeats (2  72 bp  34 bp). Primers used for amplification of the U3 region are indicated by arrows. Forward primer: 5TTCATAAGGCTTAGC-
CAGCTAAC3; reverse primer: 5GGTTGATCCCCGGTCATCTGGG3. (B) Sequence comparison of UCRs from different retroviral LTRs. Indicated by
vertical lines are regions harboring the consensus sequences of the YY1 motif (CGCCATTTT), C/EBP motif (TTTTGCAAG), Ikaros motif (ATGG-
GAAAAA), NFAT motif (TGGAAA), ELP motif (CAGATCAAGGTCAG), SRY motif (AAAAACAAGAAC), and Sp1/EGR1 motif (AGGGCGGGT). The
two point mutations found in some of the provirus sequences of SL3-3 LTR are marked with an arow (positions 85 and 99). The C/EBP and SRY motif
were identified by MatInspector V2.2 (http://transfec.gbf.de/) (C) The UCR sequence of SL3-3 wt and the six mutant viruses, with the UCR core motif
underlined. The triple basepair mutations are indicated in bold.
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that this NFAT binding site may be absent from the LTR of
the endogenous MLV of the BALB/c strain used by Flana-
gan et al. (1989) (Flanagan et al., 1992). Hence, although
these studies of retroviral vectors indicate that U3 sequences
upstream of the enhancer may have positive as well as
negative effects on expression they do not assign specific
functions to the YY1 motif. The reported negative effect of
the UCR and its YY1 motif may seem contradictive to its
strong conservation among MLVs, in particular since mo-
lecular evolution toward more potent viruses is commonly
observed in mouse models of MLV pathogenicity. How-
ever, the possibility remains that the negative effect results
from specialized conditions of the assay system, including
the cell cultures used. Alternatively, the function of the YY1
motif may depend on the wider context of the LTR and
hence differ among strains of MLV. Conceivably, such
context-dependent negative effects may be more pro-
nounced for LTRs endogenous to the mouse genome than
for LTRs of viruses selected for tumorigenic properties.
To investigate the role of the UCR and its YY1-motif in
an in vivo model of MLV–host interactions we have chosen
the potent T-lymphomagenic SL3-3 MLV. The LTR of
SL3-3 is more closely related to the endogenous LTR used
for assigning a negative function to the UCR than are the
other prototypic, potently pathogenic MLVs. We have in-
troduced six consecutive triple basepair mutations within
and adjacent to the YY1 motif in the UCR of this virus. We
here report that all mutants have retained their replication
competence and that they all, like the wild-type (wt) SL3-3
induce T-cell lymphomas when injected into newborn mice
of the SWR strain. However, all mutants induced disease
with slightly shorter latency periods than the wt SL3-3,
suggesting the YY1 motif as well as its immediate context
in the UCR has a negative effect on the pathogenicity of the
virus.
Results
Generation of SL3-3 viruses with mutations in the YY1
motif of the UCR
Six mutants were generated to investigate the role of the
YY1 binding site for the lymphomagenicity of SL3-3. The
mutations were designed on basis of the YY1-binding stud-
ies done by Flanagan et al. (1992). Using the exact same
nucleotide changes and nomenclature (Fig. 1C) the mutants
ucrSK328, ucrSK330, ucrSK332, ucrSK334, ucrSK336,
and ucrSK338 were designed. Among these, ucrSK330,
ucrSK332, and ucrSK334 were reported to be critical for
binding, in agreement with later studies of the DNA-binding
specificity of YY1 (Flanagan et al., 1992; Hyde-DeRuy-
scher, Jennings, and Shenk, 1995).
Pathogenicity of UCR mutants
The pathogenicity of the mutants was analyzed in the
inbred strain SWR, which does not harbor any endogenous
ecotropic proviruses. All viruses caused development of
disease within 4 months (Fig. 2). All the tumors induced
were lymphomas and with primary manifestations in spleen,
thymus, and lymph nodes, conforming to previous findings
for SL3-3-induced tumors (Ethelberg et al., 1997c; Nieves,
Levy, and Lenz, 1997). The incidences and latency periods
of disease development are given in Table 1. The SL3-3 wt
caused malignant lymphomas in all infected mice, with the
Fig. 2. Lymphoma induction in SWR mice by SL3-3 wt and six UCR mutated viruses. The cumulative incidence of malignant lymphomas is shown as a
function of the age of the mice.
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longest latency period of 107 days within the series of
viruses. All mice injected by the mutant viruses developed
malignant lymphomas. The mean latency period to lym-
phoma development was shorter for all the mutants than for
the wt SL3-3. According to the log rank test the shortening
of latency period compared to the wt was significant for all
six mutants (Table 1). Among the mutants, no significant
differences were observed.
Molecular characterization of lymphomas
By histologic examination all tumors from this study
were found to be large-cell lymphoblastic malignant lym-
phomas. No differences in tumor types induced by the
SL3-3 wt and the six UCR mutants were found. To test
whether the tumors were T-cell or B-cell lymphomas,
Southern blotting analysis was done as previously described
(Ethelberg et al., 1997a). All the 59 tumors randomly cho-
sen as representatives of different series of the mutants and
the wild type were found to contain rearrangements of the
TCR- chain locus. J2 rearrangements were detected in all
cases, whereas J1 rearrangements could be seen in only
some of the tumors. Examples of the hybridization data are
given in Fig. 3 and the results are summarized in Table 1.
No rearrangements were detected by hybridization with the
Ig probe (Fig. 3, Table 1), verifying that all tumors were T
lymphomas.
Molecular characterization of proviruses in tumor DNA
To detect integrated proviruses the Southern filters were
hybridized with an ecotropic-specific probe (Sorensen et al.,
1996). With a few possible exceptions, one to several pro-
viruses were detected in all tumors induced by wt and
mutant viruses (Fig. 3B). To test whether the SL3-3 viruses
with mutated UCR underwent reversion or other mutational
changes during the development of tumors, genomic DNA
from tumor tissues was used as template for PCR amplifi-
cation of the U3 regions from proviruses in tumors, using
the primer pair shown in Fig. 1A. All the PCRs generated
the expected 369-bp fragment (data not shown). In addition,
products larger or smaller than the 369-bp fragment were
also generated. Sequence analysis showed that most of the
additional fragments harbored duplications or deletions of
the tandem 72-bp repeats as previously reported for tumors
induced by SL3-3 (Ethelberg et al., 1997a, 1997b, 1997c;
Morrison, Soni, and Lenz, 1995; Nieves, Levy, and Lenz,
1997). Of all the 96 tumors subject to the analysis, 43%
harbored a duplication of one of the 72-bp repeats, and a
number of other types of duplications and deletions were
also detected in some of the tumors. The relative number of
tumors harboring proviruses with an altered number of
enhancer repeats did not appear to differ among the six
UCR mutants or the wt. Moreover, the sequence analysis
also demonstrated that duplications appear to occur far more
frequently than deletions, as previously reported in SL3-3
induced tumor in NMRI mice (Ethelberg et al., 1999).
Importantly, complete sequence analysis of a total of 135
nonrearranged and rearranged bands of wt and mutant vi-
ruses revealed no cases of nucleotide alterations of the
introduced mutations. Moreover, very little sequence vari-
ation was observed upstream of the enhancer for both wt
and mutant viruses. Based on this analysis of 135 bands
derived from 95 tumors, nucleotide alterations were ob-
served at only two positions [85 (C to T) and 99 (A to C),
Fig. 1C] between the YY1 motif and the enhancer. These
changes were seen as a mixture with the parental sequence
and were detected frequently in bands of both wt and mu-
tant. Our data do not allow us to assign any significance to
these changes.
Discussion
We have addressed the function of the YY1 motif and
flanking sequences of the UCR of MLV in a pathogenesis
model of induction of T-lymphomas by SL3-3 MLV. In
case of transcription factor sites within the enhancer it has
been amply demonstrated that the alteration of just a few
nucleotides of one recognition site may affect the tumori-
genic potency of the virus. Tumor induction may in fact
provide a sensitive assay for the contribution of individual
sites, whose effects may be amplified during multiple
rounds of replication. Moreover, insertional activation of
Table 1
Induction of lymphomas in SWR mice by SL3-3 wt and mutant UCR virus
Virus No. of mice with
malignant lymphomas/
no. of mice analyzed
Mean latency
period (days)








SL3-3 wt 9/9 107  29 0.000 5/5 0/5
ucrSK328 10/11 93  22 0.0198 10/10 0/10
ucrSK330 20/20 80  19 0.0278 10/10 0/10
ucrSK332 23/27 82  16 0.0183 10/10 0/10
ucrSK334 18/18 84  39 0.015 10/10 0/10
ucrSK336 21/21 77  18 0.0164 6/6 0/6
ucrSK338 19/19 84  18 0.0147 6/6 0/6
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oncogenes may be sensitive to enhancer strength. In addi-
tion, less understood aspects of the disease process, such as
apoptosis caused by viral infection, may depend upon viral
replication kinetics and enhancer strength in a complex
manner.
Our results show that mutations that will disrupt the
binding of YY1 to its target DNA caused a shortening of the
mean latency period of disease induction by 15–25 days as
compared to the latency period for the wt SL3-3 of 107
days. This shortening is significant and suggests that bind-
ing of YY1 to the UCR may have a negative effect on
disease induction. However, the control mutations intro-
duced in sequences adjacent to the YY1 binding site had a
similar impact on disease induction. Although there was no
significant difference among the six mutants the latency
periods for disease induction were shorter than that ob-
served for the wt in all cases. Hence, the effect on disease
induction does not correlate with the predicted change in the
binding of YY1 to DNA as observed by in vitro studies
(Flanagan et al., 1992).
We must therefore propose more complex or alternative
mechanisms to explain our results. One possibility is that all
mutations reduce the binding of a protein complex consist-
ing of YY1 as well as other proteins. Such a complex may
recognize nucleotides within as well as adjacent to the YY1
motif. Although we have no clues as to the nature of such a
complex, we note that YY1 function may be mediated by
association with other proteins (Thomas and Seto, 1999).
The DNA-bending properties of YY1 may contribute to the
overall function, promoting or preventing the binding of
nearby transcription factors to nearby binding sites (Ayuk et
al., 1999; Rao, Luo, and Hogan, 1997). An alternative
explanation is that we have hit a binding motif that recog-
nizes another protein or protein complex that does not
contain YY1. In the context of SL3-3 LTR, several tran-
scription factor binding sites (Fig. 1B) are either overlap-
ping with (C/EBP) or located immediately downstream
(Ikaros) of the YY1 binding site, which determines a com-
plex environment for delineating the exact roles of YY1 in
SL3-3 transcription.
Transcriptional silencing has been a significant obstacle
to achieving persistent expression from retroviral vectors in
vivo. Studies have shown that multiple factors may contrib-
ute to this process, one of which is the viral DNA se-
quences, including the UCR. By using an assay of vector
silencing in transplanted fibroblasts, it was recently reported
that either the disruption or deletion of the UCR resulted in
the relief of transcriptional silencing (Prasad Alur et al.,
2002). Another recent report addressed the role of the UCR
for expression of retroviral vectors in hematopoietic cell
Fig. 3. Molecular characterization of tumors by Southern blotting analysis. Genomic DNA from tumors was digested with HindIII, resolved on a 0.8% agarose
gel, blotted onto a memebrane, and hybridized with probes as indicated under each blot (J1 and J2)(TCR), Igk, and Eco. (A) Genomic DNA prepared from
SL3-3 wt-induced tumors (lane 1–5). Control DNAs (CS and CB) were isolated from spleens of mock-injected SWR and BALB/c mice, respectively. Arrows
indicate sites of unrearranged germ line fragments (J1, J2, and Igk). (B) Genomic DNA prepared from mutant- (ucrSK328) induced tumors (lane 1–10).
Arrows and size markers as in A.
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lines (Wahlers et al., 2002a). Although this latter work
identified a positive role of the NFAT motif of myelopro-
liferative sarcoma virus and Friend spleen focus-forming
virus, the role of the YY1 motif was not directly addressed.
Still another report has demonstrated that the Ikaros binding
motif in the enhancer region upregulates the transcription
from the U3 region of MCF 247 (DiFronzo et al., 2002).
However, the function of the Ikaros motif in the upstream
region remains to be elucidated.
All SL3-3 mutant viruses analyzed in the present study
resulted in increased pathogenicity in mice, indicating that
the mutated UCR may contribute to relief from transcrip-
tional silencing by an unknown mechanism, to an increase
in proviral enhancer strength, or a combination hereof. Our
results suggest that the YY1 motif and its immediate context
may be relevant targets for optimizing the LTRs of retro-
viral vectors toward improved function in T-lymphoid cells.
Materials and methods
Generation of viral mutants
Mutations were introduced into a molecular clone of
SL3-3 by oligonucleotide directed mutagenesis as described
(Hallberg et al., 1991; Lovmand et al., 1998), and U5-U3
and R-regions were confirmed by sequence analysis. All six
mutant viruses replicated on NIH 3T3 fibroblasts as judged
by reverse transcriptase assays. Polymerase chain reaction
(PCR) sequence analysis of the SL3-3UCR in the resulting
cultures (using the primers shown in Fig. 1) revealed full
conservation of the introduced mutations (data not shown).
Induction of tumors
About 36-h-old newborns were inoculated with approx-
imately 1  105 infectious centers of virus and kept under
daily inspection until development of disease. Tumors were
diagnosed on the basis of gross appearance of lymphoid
organs as previously described (Schmidt et al., 1984), com-
bined with cytologic and anatomic criteria (Pattengale,
1994).
DNA extraction and sequence verification of proviruses
Genomic DNA was extracted by DNeasy Tissue kit
(Qiagen). The PCR primers used for sequence verification
(Fig. 1) will amplify a 369-bp viral fragment that includes
all the two-and-a-half 72-bp repeats as well as the UCR
sequence. PCR products were analyzed by agarose gel elec-
trophoresis and sequenced on an automated ABI 373 DNA
sequencer using the sequencing primer 5TTGAGA-
CAGTTTCTGGGTCTCTTGAAACTGTTGTTG3.
Southern blotting
Tumor DNAs were digested with HindIII, resolved on a
0.8% agarose gel, blotted onto a membrane, and hybridized
with following probes: J1 and J2 (TCR- chain joining
region 1 and 2, respectively), Ig (immunologlobulin-),
and Eco (ecotropic envelope) as described previously (Am-
toft et al., 1997).
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